logo-loader
HealthCannabis
CB2 Insights

Cb2 Insights signs letter of Intent with UK company, Drug Science for research program TWENTY21

CB2 Insights (CSE: CBII-OTCQB: CBIIT) CEO Prad Sekar joined Steve Darling on Skype from London with news the company has been selected as an exclusive research technology platform for the UK’s largest medical cannabis Pilot – Project TWENTY21

Sekar told Proactive about that project and how CB2 will be involved.

 

Quick facts: CB2 Insights

Price: $0.16

Market: CSE
Market Cap: $12.45 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CB2 Insights named herein, including the promotion by the Company of CB2 Insights in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Greatland Gold 'inspiring the junior mining market' - Mining Capital's...

Mining Capital's Alastair Ford discusses Greatland Gold (LON:GGP) following on from a near 30-page write up on the company this week from analyst Numis. Ford talks through what it is about Greatland that he thinks warrants this special attention and with a market capitalisation now over...

38 minutes ago

2 min read